Entecavir maleate versus Entecavir in Chinese patients with HBeAg-Positive Chronic Hepatitis B: Results at 48 and 96 weeks of a Randomized Double-blind Multicenter Clinical Trial

被引：0
|
作者：
Yu, Yanyan [1 ]
Xu, Jinghang [1 ]
Tang, Hong [2 ]
Zhang, Dazhi [3 ]
Mao, Qing [4 ]
Li, Jun [5 ]
Xu, Zhongnan [6 ]
Zhang, Xiquan [6 ]
Dai, Jun [6 ]
Si, Chongwen [1 ]
机构：
[1] Peking Univ, Dept Infect Dis, Hosp 1, Beijing 100871, Peoples R China
[2] Sichuan Univ, Dept Infect Dis, W China Hosp, Chengdu 610064, Peoples R China
[3] Chongqing Med Univ, Dept Infect Dis, Affiliated Hosp 2, Chongqing, Peoples R China
[4] Third Mililary Med Univ, Dept Infect Dis, Affiliated Hosp 1, Chongqing, Peoples R China
[5] Nanjing Med Univ, Dept Infect Dis, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
[6] Jiangsu Chia Tai Tianqing Pharmaceut Co Ltd, Nanjing, Jiangsu, Peoples R China
来源：
HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
417
引用
收藏
页码：397A / 398A
页数：2
相关论文
共 50 条
  • [21] Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B
    Veenstra, David L.
    Sullivan, Sean D.
    Clarke, Lauren
    Iloeje, Uche H.
    Tafesse, Eskinder
    Di Bisceglie, Adrian
    Kowdley, Kris V.
    Gish, Robert G.
    PHARMACOECONOMICS, 2007, 25 (11) : 963 - 977
  • [22] Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multi-center, double-blind, randomized controlled trial in China
    Xiaoke Li
    Ludan Zhang
    Mei Qiu
    Yi Huang
    Huanming Xiao
    Bingjiu Lu
    Yuyong Jiang
    Fuli Long
    Hui Lin
    Jinyu He
    Qikai Wu
    Mingxiang Zhang
    Li Wang
    Xiaoning Zhu
    Man Gong
    Xuehua Sun
    Jianguang Sun
    Fengxia Sun
    Wei Lu
    Weihua Xu
    Guang Chen
    Zhiguo Li
    Danan Gan
    Xianzhao Yang
    Hongbo Du
    Yong’an Ye
    Trials, 21
  • [23] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B:Study Protocol for a Multi-Center,Double-Blind Randomized-Controlled Trial
    YE Yong-an
    LI Xiao-ke
    ZHOU Da-qiao
    CHI Xiao-ling
    LI Qin
    WANG Li
    LU Bing-jiu
    MAO De-wen
    WU Qi-kai
    WANG Xian-bo
    ZHANG Ming-xiang
    XUE Jing-dong
    LI Yong
    LU Wei
    GUO Jian-chun
    JIANG Feng
    ZHANG Xin-wei
    DU Hong-bo
    YANG Xian-zhao
    GUO Hui
    GAN Da-nan
    LI Zhi-guo
    Chinese Journal of Integrative Medicine, 2018, 24 (09) : 653 - 660
  • [24] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B:Study Protocol for a Multi-Center,Double-Blind Randomized-Controlled Trial
    YE Yongan
    LI Xiaoke
    ZHOU Daqiao
    CHI Xiaoling
    LI Qin
    WANG Li
    LU Bingjiu
    MAO Dewen
    WU Qikai
    WANG Xianbo
    ZHANG Mingxiang
    XUE Jingdong
    LI Yong
    LU Wei
    GUO Jianchun
    JIANG Feng
    ZHANG Xinwei
    DU Hongbo
    YANG Xianzhao
    GUO Hui
    GAN Danan
    LI Zhiguo
    Chinese Journal of Integrative Medicine, 2018, (09) : 653 - 660
  • [25] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial
    Ye Yong-an
    Li Xiao-ke
    Zhou Da-qiao
    Chi Xiao-ling
    Li Qin
    Wang Li
    Lu Bing-jiu
    Mao De-wen
    Wu Qi-kai
    Wang Xian-bo
    Zhang Ming-xiang
    Xue Jing-dong
    Li Yong
    Lu Wei
    Guo Jian-chun
    Jiang Feng
    Zhang Xin-wei
    Du Hong-bo
    Yang Xian-zhao
    Guo Hui
    Gan Da-nan
    Li Zhi-guo
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2018, 24 (09) : 653 - 660
  • [26] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial
    Yong-an Ye
    Xiao-ke Li
    Da-qiao Zhou
    Xiao-ling Chi
    Qin Li
    Li Wang
    Bing-jiu Lu
    De-wen Mao
    Qi-kai Wu
    Xian-bo Wang
    Ming-xiang Zhang
    Jing-dong Xue
    Yong Li
    Wei Lu
    Jian-chun Guo
    Feng Jiang
    Xin-wei Zhang
    Hong-bo Du
    Xian-zhao Yang
    Hui Guo
    Da-nan Gan
    Zhi-guo Li
    Chinese Journal of Integrative Medicine, 2018, 24 : 653 - 660
  • [27] Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients - authors' reply
    Yaghoobi, M.
    Yuan, Y.
    Hunt, R. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (09) : 993 - 993
  • [28] The efficacy of entecavir treatment for up to 96 weeks in HBeAg positive chronic hepatitis B patients with high viral load
    Tang, Hong
    Yan, Li-Bo
    Chen, En-Qiang
    Yang, Wen-Bin
    Du, Ling-Yao
    HEPATOLOGY, 2012, 56 : 409A - 410A
  • [29] Association of KIR Genotypes and Haplotypes in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir
    Zhuang, YunLong
    Li, XiXi
    Li, Xiaohua
    Xu, HuiCong
    Ye, Hui
    Sun, Di
    Liu, XiangZhong
    Ren, GuiJie
    IMMUNOLOGICAL INVESTIGATIONS, 2019, 48 (04) : 333 - 344
  • [30] Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir
    Wang, Yong-Hong
    Liao, Juan
    Zhang, Dong-Mei
    Wu, Dong-Bo
    Tao, Ya-Chao
    Wang, Meng-Lan
    Chen, En-Qiang
    Tang, Hong
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (03) : 302 - 308
12345